US FDA emphasises muscle injury risk with simvastatin
This article was originally published in Scrip
Executive Summary
The US FDA issued a warning that high doses of Merck & Co's Zocor (simvastatin) as well as generics of simvastatin are linked with an increased the risk of muscle injuries. The lipid lowering ingredient is also a component of Merck's Vytorin (simvastatin plus ezetimibe) and Abbott's Simcor (simvastatin plus niacin).